ORAOV1 polyclonal antibody, anti-human

Background:
SLC22A18 is one of several tumor-suppressing subtransferable fragments located in the imprinted gene domain of 11p15. , an important tumor-suppressor gene region. Alterations in this region have been associated with the Beckwith-Wiedemann syndrome, Wilms tumor, rhabdomyosarcoma, adrenocortical carcinoma, and lung, ovarian, and breast cancer. SLC22A18 is imprinted, with preferential expression from the maternal allele. Mutations in SLC22A18 have been found in Wilms' tumor and lung cancer. Solute carrier family 22 member 18 may act as a transporter of organic cations, and have a role in the transport of chloroquine and quinidine-related compounds in kidney. Several alternatively spliced transcript variants encoding different isoforms have been described.

Research Area: Others

Synonyms: ORAOV1, TAOS1, Oral cancer-overexpressed protein 1, Tumor-amplified and overexpressed sequence 1

Immunogen: The antiserum was produced against synthesized peptide derived from human AMPK alpha around the phosphorylation site of Thr172. AA range:140-189

Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Formulation: Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Concentration: 1 mg/ml

Storage:
-20°C for 1 year